|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date25 Jun 2018 |
A Phase 2a, open label, multicenter, study to evaluate the pharmacokinetic (PK) profile, safety and efficacy of multiple doses of Cannabidiol (CBD) for the prevention of Acute Graft-Versus-Host Disease (GVHD) after allogeneic hematopoietic cell transplantation (HSCT)
A Phase 2a, Open-label, Multicenter, Study to Evaluate the Pharmacokinetic (PK), Safety and Efficacy of Multiple Doses of Cannabidiol for the Prevention of aGVHD After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
A prospective, open-label, phase 2a study, to evaluate the pharmacokinetic (PK) profile, safety, and efficacy of multiple doses of Cannabidiol (CBD) in participants Graft-Versus-Host Disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT)
100 Clinical Results associated with Kalytera Therapeutics Israel, Ltd.
0 Patents (Medical) associated with Kalytera Therapeutics Israel, Ltd.
100 Deals associated with Kalytera Therapeutics Israel, Ltd.
100 Translational Medicine associated with Kalytera Therapeutics Israel, Ltd.